The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. (Q34418847)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25360245%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

review article

1 reference

title

The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25360245%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25360245%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25360245%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Vicent Balanzá-Martínez

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25360245%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Miguel Ruiz Veguilla

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25360245%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

publication date

1 October 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25360245%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

number of pages

1 reference

Therapeutic advances in psychopharmacology

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25360245%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25360245%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25360245%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

page(s)

198-219

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25360245%20AND%20SRC:MED&resulttype=core&format=json

Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness

22 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Patients' and clinicians' attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Systematic review of the economic aspects of nonadherence to antipsychotic medication in patients with schizophrenia

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Safety and efficacy review of inhaled loxapine for treatment of agitation

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Long-acting injectable antipsychotics and the development of postinjection delirium/sedation syndrome (PDSS).

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Attitudes towards the administration of long-acting antipsychotics: a survey of physicians and nurses

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

History and therapeutic rationale of long acting antipsychotics

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Long-acting injectable antipsychotics in early psychosis: a literature review

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Should long-acting (depot) antipsychotics be used in early schizophrenia? A systematic review

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Treatment adherence with early prescription of long-acting injectable antipsychotics in recent-onset schizophrenia

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Long-acting injectable antipsychotics in first-episode schizophrenia

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Rethinking the role of long-acting atypical antipsychotics in the community setting

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

The Potential Role of Long-acting Injectable Antipsychotics in People with Schizophrenia and Comorbid Substance Use.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Symptom recurrence following intermittent treatment in first-episode schizophrenia successfully treated for 2 years: a 3-year open-label clinical study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS).

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Antipsychotic prophylaxis is needed after remission from a first psychotic episode in schizophrenia patients: results from an aborted randomised trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Clinical pharmacology of paliperidone palmitate a parenteral long-acting formulation for the treatment of schizophrenia

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Progressive pathology is functionally linked to the domains of language and emotion: meta-analysis of brain structure changes in schizophrenia patients

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Neurotoxic/neuroprotective activity of haloperidol, risperidone and paliperidone in neuroblastoma cells

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Long acting injection versus oral risperidone in first-episode schizophrenia: differential impact on white matter myelination trajectory

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Opinions of French patients with schizophrenia regarding injectable medication

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Oral versus depot antipsychotic drugs for schizophrenia—A critical systematic review and meta-analysis of randomised long-term trials

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

A Prospective Study Comparing the Long-term Effectiveness of Injectable Risperidone Long-acting Therapy and Oral Aripiprazole in Patients with Schizophrenia

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Proton magnetic resonance spectroscopy and illness stage in schizophrenia--a systematic review and meta-analysis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Strategies for addressing adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Relapse prevention in first-episode schizophrenia--maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Who needs antipsychotic medication in the earliest stages of psychosis? A reconsideration of benefits, risks, neurobiology and ethics in the era of early intervention

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Update on the use of MR for assessment and diagnosis of psychiatric diseases

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Historical perspective on antipsychotic long-acting injections

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Clinical guideline recommendations for antipsychotic long-acting injections

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Attitudes of patients and mental health staff to antipsychotic long-acting injections: systematic review

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Experience with injectable long-acting risperidone in long-term therapy after an acute episode of schizophrenia: the SPHERE Study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Pharmacokinetics and efficacy of a direct switch from conventional depot to risperidone long-acting injection in Chinese patients with schizophrenic and schizoaffective disorders.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR).

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

The metabolic syndrome and schizophrenia

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Understanding and addressing adherence issues in schizophrenia: from theory to practice.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Early intervention in psychotic disorders: detection and treatment of the first episode and the critical early stages

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

In vitro and in vivo demonstration of risperidone implants in mice.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Risks versus benefits of different types of long-acting injectable antipsychotics.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Effectiveness of community treatment orders for treatment of schizophrenia with oral or depot antipsychotic medication: clinical outcomes

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness models

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

The Economic Burden of Schizophrenia in the United States in 2002

6 July 2018

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

6 July 2018

https://api.crossref.org/works/10.1177%2F2045125314540297

First-episode schizophrenia: a focus on pharmacological treatment and safety considerations

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Clinical review of a long-acting, injectable formulation of risperidone

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Remission in schizophrenia: proposed criteria and rationale for consensus

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Relapse in schizophrenia: costs, clinical outcomes and quality of life

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

An audit of outpatient antipsychotic usage in the three health sectors of Auckland, New Zealand

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Practice guideline for the treatment of patients with schizophrenia, second edition.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Relapse and rehospitalization: comparing oral and depot antipsychotics.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

The long-acting depot antipsychotic drugs

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Predictors of noncompliance in patients with schizophrenia.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Systematic review of patient and nurse attitudes to depot antipsychotic medication.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Systematic meta-review of depot antipsychotic drugs for people with schizophrenia

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Prediction of homelessness within three months of discharge among inpatients with schizophrenia

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Early intervention in psychosis. The critical period hypothesis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Clozapine withdrawal effects and receptor profiles of typical and atypical neuroleptics

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Depot neuroleptic therapy: clinical considerations

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Depot neuroleptics in relapse prevention: advantages and disadvantages.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Depot antipsychotic drugs. Place in therapy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Prevention of relapse in schizophrenia. An evaluation of fluphenazine decanoate

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Costs and benefits of two doses of fluphenazine

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Depot fluphenazine: risk/benefit ratio

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months' treatment for relapse prevention.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Chemotherapy with neuroleptics. Clinical and pharmacokinetic aspects with a particular view to depot preparations

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Clinical pharmacokinetics of the depot antipsychotics

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

The Scottish first episode schizophrenia study. VII. Two-year follow-up. Scottish Schizophrenia Research Group

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Pharmacokinetics of long-acting injectable neuroleptic drugs: clinical implications

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Depot neuroleptic therapy: an underutilized treatment option

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Temporal Effects of Drug and Placebo in Delaying Relapse in Schizophrenic Outpatients

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. I. Relapse rates after one year

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Fluphenazine decanoate vs oral antipsychotics: a comparison of their effectiveness in the treatment of schizophrenia as measured by a reduction in hospital readmissions

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Outcome of common mental disorders in Harare, Zimbabwe

6 July 2018

1 reference

https://api.crossref.org/works/10.1177%2F2045125314540297

Symptomatic remission in schizophrenia patients: relationship with social functioning, quality of life, and neurocognitive performance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2045125314540297

Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2045125314540297

Medication adherence of individuals with a first episode of psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2045125314540297

Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2045125314540297

Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2045125314540297

Neurocognitive function in long-term treated schizophrenia: a five-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2045125314540297

Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2045125314540297

Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2045125314540297

Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2045125314540297

Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2045125314540297

Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2045125314540297

Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2045125314540297

Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2045125314540297

Pharmacokinetic studies in volunteers of intravenous and oral cis (Z)-flupentixol and intramuscular cis (Z)-flupentixol decanoate in Viscoleo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2045125314540297

Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2045125314540297

Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2045125314540297

Association of violence with emergence of persecutory delusions in untreated schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2045125314540297

Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2045125314540297

Comparison of attitudes toward long-acting injectable antipsychotics among psychiatrists and patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2045125314540297

The global costs of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2045125314540297

Discovering the neural basis of human social anxiety: a diagnostic and therapeutic imperative

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2045125314540297

Healthcare cost reductions associated with the use of LAI formulations of antipsychotic medications versus oral among patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2045125314540297

The case for practical clinical trials in psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2045125314540297

Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2045125314540297

Psychiatrists' use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2045125314540297

Trends in the Rate and Type of Antipsychotic Medications Prescribed to Persons With Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2045125314540297

The influence of switching from haloperidol decanoate depot to risperidone long-acting injection on the clinical symptoms and cognitive function in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2045125314540297

On the path to recovery: patients' experiences of treatment with long-acting injections of antipsychotic medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2045125314540297

Effects of involuntary outpatient commitment and depot antipsychotics on treatment adherence in persons with severe mental illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2045125314540297

Risperidone long-acting injection: pharmacokinetics following administration in deltoid versus gluteal muscle in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2045125314540297

A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2045125314540297

Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2045125314540297

Community treatment orders: relationship to clinical care, medication compliance, behavioural disturbance and readmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2045125314540297

Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2045125314540297

Quality of life of schizophrenic patients treated with haloperidol depot and injection preparation of long-lasting risperidone.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Formulation optimization of long-acting depot injection of aripiprazole by using D-optimal mixture design.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Who receives long-acting antipsychotic medications?

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Clinical practice guidelines. Treatment of schizophrenia.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Naturalistic, retrospective comparison between second-generation antipsychotics and depot neuroleptics in patients affected by schizophrenia.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Rehospitalization risk with second-generation and depot antipsychotics

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Does evidence from clinical trials in psychopharmacology apply in clinical practice?

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4212490

Guidelines for depot antipsychotic treatment in schizophrenia

27 October 2018

1 reference

https://api.crossref.org/works/10.1177%2F2045125314540297

Fluctuation of serum zuclopenthixol concentrations in patients treated with zuclopenthixol decanoate in viscoleo

21 January 2018

1 reference

12 December 2020

Identifying the profile of optimal candidates for antipsychotic depot therapy A cluster analysis

1 reference

12 December 2020

The contribution of fluphenazine enanthate and decanoate in the prevention of readmission of schizophrenic patients

1 reference

12 December 2020

Health resource utilization associated with switching to risperidone long-acting injection

1 reference

12 December 2020

Attitudes of psychiatrists toward antipsychotic depot medication

1 reference

12 December 2020

Flupenthixol decanoate--in treatment of out-patients

1 reference

12 December 2020

Prediction of the optimal perphenazine decanoate dose based on blood samples drawn within the first three weeks

1 reference

12 December 2020

Design of a long-term antipsychotic in situ forming implant and its release control method and mechanism

1 reference

12 December 2020

A randomised controlled trial of prophylactic neuroleptic treatment

1 reference

12 December 2020

The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment

1 reference

12 December 2020

Pharmacokinetics of haloperidol decanoate. A 2-year follow-up

1 reference

12 December 2020

Clinicians' attitudes toward the use of long-acting injectable antipsychotics

1 reference

12 December 2020

A mirror image Out-patient study at a depot phenothiazine clinic

1 reference

12 December 2020

Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes

1 reference

12 December 2020

Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study

1 reference

12 December 2020

Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone

1 reference

12 December 2020

The attitude of patients towards antipsychotic depot treatment

1 reference

12 December 2020

[Categorical refusal of treatment by psychiatric patients: balance, survey and prospects]

1 reference

12 December 2020

Fluphenazine vs Placebo in Patients With Remitted, Acute First-Episode Schizophrenia

1 reference

12 December 2020

Blood and plasma kinetics of cis(Z)-clopenthixol and fluphenazine in psychiatric patients after intramuscular injection of their decanoic esters

1 reference

12 December 2020

Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment

1 reference

12 December 2020

Depot and oral antipsychotics: patient preferences and attitudes are not the same thing

1 reference

12 December 2020

The use of depot medications in the treatment of schizophrenia

1 reference

12 December 2020

Healthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs oral

1 reference

12 December 2020

[Long-acting injectable antipsychotics: an expert opinion from the Association des médecins psychiatres du Québec]

1 reference

12 December 2020

First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies

1 reference

12 December 2020

Identifiers

DOI

10.1177/2045125314540297

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25360245%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25360245%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

PubMed publication ID

25360245

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25360245%20AND%20SRC:MED&resulttype=core&format=json